Evidence map›Paper›PMID 33499924›Full record

ArticleGenome biology2021

The evolution of alternative splicing in glioblastoma under therapy.

Lin Wang, Karin Shamardani, Husam Babikir, Francisca Catalan, Takahide Nejo, Susan Chang, Joanna J Phillips, Hideho Okada, Aaron A Diaz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lin Wang *Department of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Karin Shamardani *Department of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Husam BabikirDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Francisca CatalanDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Takahide NejoDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Susan ChangDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Hideho OkadaDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Aaron A DiazDepartment of Neurological Surgery, University of California, San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA. aaron.diaz@ucsf.edu.ORCID 0000-0001-9059-9501
University of California, San Francisco · US

Funding

Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0M
6 · The paper itself

Abstract

backgroundAlternative splicing is a rich source of tumor-specific neoantigen targets for immunotherapy. This holds promise for glioblastomas (GBMs), the most common primary tumors of the adult brain, which are resistant to standard-of-care therapy. Although most clinical trials enroll patients at recurrence, most preclinical studies have been done with specimens from primary disease. There are limited expression data from GBMs at recurrence and surprisingly little is known about the evolution of splicing patterns under therapy.

resultWe profile 37 primary-recurrent paired human GBM specimens via RNA sequencing. We describe the landscape of alternative splicing in GBM at recurrence and contrast that to primary and non-malignant brain-tissue specimens. By screening single-cell atlases, we identify cell-type-specific splicing patterns and novel splicing events in cell-surface proteins that are suitable targets for engineered T cell therapies. We identify recurrent-specific isoforms of mitogen-activated kinase pathway genes that enhance invasiveness and are preferentially expressed by stem-like cells.

conclusionThese studies shed light on gene expression in recurrent GBM and identify novel targets for therapeutic development.

Indexed as

Alternative SplicingEvolution, MolecularBrainBrain NeoplasmsGene Expression Regulation, NeoplasticGlioblastomaHumansIntracellular Signaling Peptides and ProteinsProtein IsoformsProtein Serine-Threonine KinasesRNA-Binding ProteinsT-LymphocytesIntracellular Signaling Peptides and ProteinsMAP4K4 protein, humanProtein IsoformsProtein Serine-Threonine KinasesRNA-Binding Proteins

Identifiers

PMID33499924
PMCPMC7835670
OpenAlexW3121770643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.